Affiliation: University of Pisa
Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos R, Sherman S, et al
. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2009;94:4171-9 pubmed publisher
Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, et al
. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab. 2012;97:4390-8 pubmed publisher
..In particular, the high negative predictive value of the BRAF(V600E) mutation could be useful to identify, among low-risk PTC patients, those who could avoid 131-I treatment. ..
Elisei R, Cosci B, Romei C, Agate L, Piampiani P, Miccoli P, et al
. Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition. J Clin Endocrinol Metab. 2004;89:5823-7 pubmed
..The analysis of several RET polymorphisms also confirmed the presence of two mutated alleles in MTC affected patients and both mutated and wild-type allele in heterozygous subjects. ..
Elisei R, Vivaldi A, Ciampi R, Faviana P, Basolo F, Santini F, et al
. Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid. J Clin Endocrinol Metab. 2006;91:2389-95 pubmed
Elisei R. Routine serum calcitonin measurement in the evaluation of thyroid nodules. Best Pract Res Clin Endocrinol Metab. 2008;22:941-53 pubmed publisher
..The differential diagnosis is possible using previously validated assays against possible sources of interference, and performing stimulation tests with pentagastrin or, eventually, calcium infusion. ..
Elisei R, Molinaro E, Agate L, Bottici V, Masserini L, Ceccarelli C, et al
. Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab. 2010;95:1516-27 pubmed publisher
..Despite these significant differences, both advanced stage and older age still represent the most important poor prognostic factors for survival. ..
Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, et al
. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab. 2008;93:3943-9 pubmed publisher
..In particular, the BRAF(V600E) mutation was demonstrated to be a poor prognostic factor independent from other clinicopathological features. ..
Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, et al
. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab. 2008;93:682-7 pubmed
..More interestingly, the presence of a somatic RET mutation correlates with the presence of lymph node metastases at diagnosis, which is a known bad prognostic factor for the definitive cure of MTC patients. ..
Elisei R, Cosci B, Romei C, Bottici V, Sculli M, Lari R, et al
. RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. J Clin Endocrinol Metab. 2004;89:3579-84 pubmed
..A putative role of the G691S polymorphism as genetic modifier in the normal subjects remains to be established...